Detail akcie Genscript Biotech online

Business Summary: Genscript Biotech Corp is a company primarily engaged in bioscience research and related businesses. The Company operates through four segments. The Life-Science Services and Products segment provides comprehensive reagent services and products, instruments and custom-tailored solutions for gene therapy, cell therapy, antibody therapeutics, vaccines and diagnostics. The Biologics Development Services segment provides comprehensive services aimed to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment provides industrial enzyme development and production by non-pathogenic microbial strains constructed using genetic engineering. The Cell Therapy segment is engaged in the discovery and development of novel cell therapies for oncology and other indications.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Genscript Biotech Corp revenues increased 6% to $594.5M. Net loss before extraordinary items totaled $67.2M vs. income of $422.5M. Revenues reflect United States of America segment increase of 5% to $265.1M, Europe segment increase of 17% to $80.9M. Net loss reflects Fair Value Adjustments on Other Assets increase from $129.2M (income) to $123.6M (expense).